Cargando…
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry
In the past two decades, immunotherapy has established itself as one of the leading strategies for cancer treatment, as illustrated by the exponentially growing number of related clinical trials. This trend was, in part, prompted by the clinical success of both immune checkpoint modulation and immun...
Autores principales: | Thoreau, Fabien, Chudasama, Vijay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826860/ https://www.ncbi.nlm.nih.gov/pubmed/35360884 http://dx.doi.org/10.1039/d1cb00082a |
Ejemplares similares
-
Dual reactivity disulfide bridging reagents; enabling new approaches to antibody fragment bioconjugation
por: Chrzastek, Alina, et al.
Publicado: (2022) -
Enabling the formation of native mAb, Fab′ and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs)
por: Thoreau, Fabien, et al.
Publicado: (2023) -
Next generation Fc scaffold for multispecific antibodies
por: Estes, Bram, et al.
Publicado: (2021) -
Tyrosine bioconjugation – an emergent alternative
por: Szijj, Peter A., et al.
Publicado: (2020) -
Correction: Tyrosine bioconjugation – an emergent alternative
por: Szijj, Peter A., et al.
Publicado: (2022)